The Global Syphilis Testing Market is valued at approximately USD 1.30 billion in 2023 and is projected to grow with a steady CAGR of 5.6% over the forecast period 2024-2032. Syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum, remains a significant public health concern worldwide. The disease manifests in multiple stages, with the first stage being latent and often asymptomatic, making it challenging to detect. As syphilis progresses into its tertiary stage, it can cause severe health complications, including multi-organ infections, neurological damage, and vascular issues. The market for syphilis testing is thus crucial for early diagnosis and effective management of the disease.
The Syphilis Testing Market is driven by several key factors, including a rising incidence and prevalence of syphilis, particularly among high-risk populations such as men who have sex with men (MSM), injecting drug users, and sex workers. The asymptomatic nature of the disease during its infectious phase makes it a silent threat, often spreading undetected. The implementation of comprehensive screening programs and increased awareness of sexual health are vital in controlling the spread of syphilis, further fueling the demand for syphilis testing. Additionally, favorable reimbursement policies for sexually transmitted diseases (STDs) testing and advancements in syphilis testing kits contribute to the market's growth. The growing geriatric population, which is more susceptible to infections, also plays a role in expanding the syphilis testing market.
The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. In 2023, North America held the largest share of the market, driven by high awareness levels, advanced healthcare infrastructure, and the availability of sophisticated diagnostic tools. Europe followed closely, with its strong public health initiatives and robust screening programs. Meanwhile, the Asia-Pacific region is anticipated to witness the fastest growth during the forecast period, attributed to rising healthcare awareness, improving healthcare infrastructure, and an increasing focus on sexual health education.
Major market players included in this report are:
Becton Dickinson and Company
DiaSorin
Siemens Healthcare
Bio-Rad Laboratories
Hologic, Inc.
F. Hoffmann-La Roche
Beckman Coulter
Cepheid Inc.
Affymetrix, Inc.
Abbott Laboratories
BioMerieux
Astam Diagnostic
Thermo Fisher Scientific Inc.
Meridian Bioscience
OraSure Technologies
The detailed segments and sub-segments of the market are explained below:
By Type:
Primary & Secondary Syphilis
Others
By Location of Testing:
Laboratory Testing
Point of Care (POC) Testing
By Region:
North America:
U.S.
Canada
Europe:
Germany
France
UK
Italy
Spain
Rest of Europe
Asia Pacific:
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
Latin America:
Brazil
Mexico
Rest of Latin America
Middle East and Africa
Saudi Arabia
South Africa
Rest of Middle East and Africa
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of the geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.
